

Designated Drugs Regulation

1. For the purpose of paragraph 2.1 of section 4 of the *Act*, a member may prescribe a drug set out in Schedule 1 to this Regulation if the member complies with the standards of practice set out in section 2.
2. It is a standard of practice of the profession that a member who prescribes a drug shall first have successfully completed relevant training in pharmacology that has been approved by the Council.
3. It is a standard of practice of the profession that a member who prescribes a drug shall record in the member's patient record details of the prescription and of the counselling provided by the member to or on behalf of the patient respecting the use of that drug.
4. It is a standard of practice of the profession that a member who prescribes an oral antibacterial or oral antiviral drug set out in Schedule 1 shall only prescribe that drug for the treatment of corneal or eyelid infections.
5. (1) The following are standards of practice of the profession applicable to the treatment of a patient with glaucoma:
 1. Except as provided for in paragraph 2 and subject to paragraph 3, a member may treat a patient having primary open-angle glaucoma and, where appropriate, may prescribe a drug set out in Schedule 1 for topical application for that patient.
 2. Subject to paragraph 3, a patient having primary open-angle glaucoma, the treatment of which is complicated by a concurrent medical condition, shall be immediately referred by the member to a physician or to a hospital.
 3. A member may treat a patient having primary open-angle glaucoma, the treatment of which is complicated by a concurrent medical condition, so long as the treatment is provided in collaboration with a physician with whom the member has established a co-management model of care for that patient.
 4. Subject to paragraphs 5 and 6, a patient having a form of glaucoma other than primary open-angle glaucoma, shall be immediately referred by the member to a physician or to a hospital.
 5. A member may treat a patient having a form of glaucoma other than primary open-angle glaucoma so long as the treatment is provided in collaboration with a physician with whom the member has established a co-management model of care for that patient.
 6. A member may initiate treatment for a patient having angle-closure glaucoma but where the member does so, the member shall immediately refer the patient to a physician or to a hospital.
- (2) The standards of practice referred to in subsection (1) do not apply to the treatment of elevated intraocular pressure secondary to anterior uveitis.

SCHEDULE 1

Anti-infectives

Topical antibacterials

azithromycin
bacitracin
besifloxacin
chloramphenicol
ciprofloxacin
erythromycin
framycetin
fusidic acid
gatifloxacin
gentamicin
moxifloxacin
ofloxacin
polymyxin B/bacitracin
polymyxin B/gramicidin
polymyxin B/gramicidin/neomycin
polymyxin B /neomycin/ bacitracin
polymyxin B /trimethoprim
sulfacetamide sodium
tetracycline
tobramycin

Topical antifungals

natamycin (**Special Access Program**)

Topical antivirals

trifluridine
acyclovir (**Special Access Program**)

Oral antibiotics

amoxicillin
amoxicillin/clavulanic acid
azithromycin
cephalexin
ciprofloxacin
clarithromycin
clindamycin
cloxacillin
doxycycline
erythromycin
levofloxacin

minocycline
moxifloxacin
tetracycline

Oral antivirals

acyclovir
famciclovir
valacyclovir

Anti-inflammatories

Topical corticosteroids

dexamethasone
dexamethasone sodium phosphate
fluorometholone
fluorometholone acetate
loteprednol
prednisolone acetate
prednisolone sodium phosphate
rimexolone

Topical nonsteroidal anti-inflammatories

diclofenac sodium
ketorolac tromethamine
nepafenac

Anti-infective/anti-inflammatory combinations

chloramphenicol/hydrocortisone
framycetin/gramicidin/dexamethasone
gentamicin/betamethasone sodium phosphate
neomycin/fluorometholone
neomycin/ polymyxin B/dexamethasone sodium phosphate
neomycin/bacitracin/polymyxin B /hydrocortisone
sodium sulfacetamide/prednisolone acetate
tobramycin/dexamethasone sodium phosphate
tobramycin/loteprednol

Cycloplegic/mydriatic agents

atropine
cyclopentolate
homatropine

Anti-allergic agents

Topical decongestants

naphazoline
phenylephrine
oxymetazoline
tetrahydrozoline

Topical antihistamines/decongestant

antazoline / naphazoline
pheniramine / naphazoline
pheniramine /phenylephrine

Topical mast cell stabilizers

lodoxamide tromethamine
nedocromil sodium
cromoglycate sodium

Topical antihistamine/mast cell stabilizers

emedastine
ketotifen
levocabastine
olopatadine

Artificial tears, ocular lubricants and secretagogues

carboxymethyl cellulose sodium
cyclosporin A (**Special Access Program**)
dextran 70/hydroxypropyl methylcellulose
glycerine
hydroxypropyl cellulose
hydroxypropyl methylcellulose
mineral oil/petrolatum
polyethelene glycol 400
polysorbate 80
polyvinyl alcohol
propylene glycol
sodium hyaluronate

Glaucoma therapy and agents to lower intraocular pressure

Beta-adrenergic receptor blockers

betaxolol
levobunolol
timolol

Carbonic anhydrase inhibitors

brinzolamide
dorzolamide

Cholinergics/miotics

carbachol
pilocarpine

Prostaglandin analogs

brimatoprost
latanoprost
travoprost

Selective alpha adrenergic receptor agonists

apraclonidine
brimonidine

Combination drugs

brimonidine/timolol
dorzolamide/timolol
latanoprost/ timolol
travoprost /timolol